康莱特注射液联合调强适形放疗同步TP化疗治疗局部晚期非小细胞肺癌临床观察  

Clinical Observation of Kanglaite Injection Combined with Intensity Modulated Conformal Radiotherapy and TP Chemotherapy in the Treatment of Locally Advanced Non-Small-Cell Lung Cancer

作　　者：杨立鑫[1] 李丹青 乔志安 王晓贞[1] 郝倩 YANG Lixin;LI Danqing;QIAO Zhi'an;WANG Xiaozhen;HAO Qian(Department of Radiotherapy,Hebei Xingtai People's Hospital,Xingtai,Hebei,China 054000;DepartmentⅡof Tuberculosis,The Second Hospital of Xingtai City,Xingtai,Hebei,China 054000)

机构地区：[1]河北省邢台市人民医院放疗科,河北邢台054000 [2]河北省邢台市第二医院结核二科,河北邢台054000

出　　处：《中国药业》2021年第24期96-100,共5页China Pharmaceuticals

基　　金：河北省中医药管理局科研计划项目[2018411]。

摘　　要：目的探讨康莱特注射液联合调强适形放射治疗(简称调强放疗)同步紫杉醇联合顺铂(TP)化疗治疗局部晚期非小细胞肺癌(LA-NSCLC)的临床疗效。方法选取邢台市人民医院2017年10月至2019年10月收治的LA-NSCLC患者90例,按随机数字表法分为观察组和对照组,各45例。两组患者均予调强放疗同步TP化疗,观察组患者加用康莱特注射液静脉滴注。两组均以3周为1个疗程,连续治疗2个疗程。结果对照组2例因4级白细胞减少而停止治疗。观察组与对照组的客观缓解率及临床获益率相当(82.22%比69.77%,95.56%比90.70%,P>0.05);与对照组比较,观察组患者治疗后的癌胚抗原、细胞角蛋白19片段抗原21-1、鳞状上皮细胞癌抗原水平均显著降低,卡氏功能状态量表评分显著升高(P<0.05);与对照组比较,观察组患者治疗后3,6周的CD_(3)^(+)和CD_(4)^(+)T淋巴细胞水平及CD_(4)^(+)/CD_(8)^(+)均显著升高,CD_(8)^(+)T淋巴细胞水平显著降低(P<0.05);观察组患者3级及以上不良反应发生率为13.33%,显著低于对照组的40.00%(P=0.004<0.05)。结论康莱特注射液联合调强放疗同步TP化疗治疗LA-NSCLC具有良好的减毒增效作用,可改善患者的生存质量,有效避免因同步放化疗所致机体免疫功能降低。Objective To investigate the clinical efficacy of Kanglaite Injection combined with intensity-modulated radiation therapy( IMRT) and paclitaxel and cisplatin( TP) chemotherapy in the treatment of locally advanced non-small-cell lung cancer( LA-NSCLC).Methods A total of 90 patients with LA-NSCLC admitted to the Xingtai People’s Hospital from October 2017 to October 2019 were selected and randomly divided into the observation group and the control group,45 cases in each group. The patients in the two groups were treated with IMRT and TP chemotherapy,and the patients in the observation group were treated with Kanglaite Injection intravenously. Both groups were treated for two consecutive courses with three weeks as a course of treatment. Results Two patients in the control group stopped treatment because of grade 4 leukocytopenia. The objective remission( OR) rate and clinical benefit( CB) rate in the observation group were similar to those in the control group( 82. 22% vs. 69. 77%,95. 56% vs. 90. 70%,P > 0. 05). The levels of carcinoembryonic antigen( CEA),cytokeratin 19 fragment antigen 21-1( CYFRA21-1) and squamous cell carcinoma antigen( SCC) in the observation group were significantly lower than those in the control group,while the Karnofsky( KPS) score in the observation group was significantly higher than that in the control group( P < 0. 05). Three and six weeks after treatment,the levels of CD_(3)^(+),CD_(4)^(+),T lymphocytes and CD_(4)^(+)/CD_(8)^(+) in the observation group were significantly higher than those in the control group,while the level of CD_(8)^(+) T lymphocytes in the observation group was significantly lower than that in the control group( P < 0. 05). The incidence of grade 3 and above adverse reactions in the observation group was 13. 33%,which was significantly lower than 40. 00% in the control group( P =0. 004 < 0. 05). Conclusion Kanglaite Injection combined with IMRT and TP chemotherapy in the treatment of patients with LA-NSCLC has a good toxic and synergistic effect,which can improv

关 键 词：局部 晚期 非小细胞肺癌 调强适形放疗 TP方案 同步放化疗 康莱特注射液 免疫功能 临床疗效 

分 类 号：R969.4[医药卫生—药理学] R979.1[医药卫生—药学]